Is neuroprotection a viable therapy for glaucoma?

Archives of Ophthalmology

Volumn 117, Issue 11, 1999, Pages 1540-1544

  Weinreb, Robert N ^a   Levin, Leonard A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NEUROTROPHIN;

DRUG MECHANISM; DRUG RESEARCH; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NEUROPROTECTION; NONHUMAN; OPTIC NERVE DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0032725983     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.117.11.1540     Document Type: Review

References (44)

1. Schumer RA, Podos SM. The nerve of glaucoma! Arch Ophthalmol. 1994;112:37-44.
2. Kolker AE. Visual prognosis in advanced glaucoma: a comparison ot medical and surgical therapy for retention of vision in 101 eyes with advanced glaucoma. Trans Am Ophthalmol. Soc. 1977;75:539-555.
3. Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol. 1987;182(suppl 65): 27-29.
4. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol. 1991;111: 51-55.
5. Sommer A, Tielsch JM, Katz J, et al. Relationship between intraocular pressure and primary open-angle glaucoma among white and black Americans. Arch Ophthalmol. 1991;109:1090-1095.
6. Preferred Practice Pattern: Primary Open-Angle Glaucoma. San Francisco, Calif: American Academy of Ophthalmology: 1992:19-22.
7. Collaborative Normal-Tension Glaucoma Study Sroup. Comparison ot glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressure. Am J Ophthalmol. 1998;126:487-497.
8. Fechtner RD, Weinreb RN. Mechanisms of optic nerve damage in primary open-angle glaucoma. Surv Ophthalmol. 1994;39:23-42.
9. Hernandez MR, Pena JDO. The optic nerve head in glaucomatous optic neuropathy. Arch Ophthalmol. 1997;115:389-395.
10. Weinreb RN. Toward understanding the optic neuropathy of glaucoma. Arch Ophthalmol. 1998; 116:1102-1103.
11. Levin LA. Intrinsic survival mechanisms for retinal ganglion cells. Eur J Ophthalmol. 1999;9:S12-S16.
12. 2-agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999;9:S17-S21.
13. Dreyer EB. A proposed role for excitotoxicity in glaucoma. J Glaucoma. 1998;7:62-67.
14. Meyer-Franke A, Kaplan MR, Pfrieger FW, Barres BA. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron. 1995; 15:805-819.
15. Minckler DS, Bunt AH, Johanson GW. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci. 1977;16:426-441.
16. Tatton WG. Apoptotic mechanisms in neurodegeneration: Possible relevance to glaucoma. Eur J Ophthalmol. 1999;9:S22-S29.
17. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today. 1997;18: 44-51.
18. Tatton WG, Chalmers-Redman RM, Ju WY, Wadia J, Tatton NA. Apoptosis in neurodegenerative disorders: potential for therapy by modifying gene transcription. J Neural Transm Suppl. 1997; 49:245-268.
19. Quigley HA, Nickells RW, Kerrigan LA, et al. Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis. Invest Ophthalmol Vis Sci. 1995;36:774-786.
20. Kerrigan LA, Zack DJ, Quigley HA, Smith SD, Pease ME. TUNEL-positive ganglion cells in human open-angle glaucoma. Arch Ophthalmol. 1997;115: 1031-1035.
21. Okisaka S, Murakami A, Mizukawa A, Ito J. Apoptosis in retinal ganglion cell decrease in human glaucomatous eyes. Jpn J Ophthalmol. 1997;41: 84-88.
22. Yoles E, Schwartz M. Potential neuroprotective therapy for glaucomatous optic neuropathy. Surv Ophthalmol. 1998;42:367-372.
23. Caprioli J. Neuroprotection of the optic nerve in glaucoma. Acta Ophthalmol Scand. 1997;75:361-367
24. Yoles E, Muller S, Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma. 1997;14:665-75.
25. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
26. Caprioli J, Kitano S, Morgan JE. Hyperthermia and hypoxia increase tolerance of retinal ganglion cells to anoxia and excitotoxicity. Invest Ophthalmol Vis Sci. 1996;37:2376-2381.
27. Levin LA. Direct and indirect approaches to neuroprotective therapy of glaucomatous optic neuropathy. Surv Ophthalmol. In press.
28. Hickenbottom SL, Grotta J. Neuroprotective therapy. Semin Neurol. 1998;18:485-492.
29. Muir KW, Grosset DG. Neuroprotection for acute stroke: making clinical trials work. Stroke. 1999; 30:180-182.
30. Mansour-Robaey S, Clarke DB, Wang YC, et al. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and re-growth of axotomized retinal ganglion cells. Proc Natl Acad Sci USA. 1994;91:1632-1636.
31. Bracken MB, Shepard MJ, Holford TR, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial: National Acute Spinal Cord Injury Study. JAMA. 1997;277:1597-1604.
32. Levin LA, Clark JA, Johns LK. Effect of lipid peroxidation inhibition on retinal ganglion cell death. Invest Ophthalmol Vis Sci. 1996;37:2744-2749.
33. Lindsey JD, Weinreb RN. Survival and differentiation of purified retinal ganglion cells in a chemically defined microenvironment. Invest Ophthalmol Vis Sci. 1994;35:3640-3648.
34. Vorwerk CK, Lipton SA, Zurakowski D, et al. Chronic low-dose glutamate is toxic to retinal ganglion cells: toxicity blocked by memantine. Invest Ophthalmol Vis Sci. 1996;37:1618-1624.
35. Pang I-H, Wexler EM, Nawy S, DeSantis L, Kapin MA. Protection by eliprodil against excitotoxicity in cultured rat retinal ganglion cells. Invest Ophthalmol Vis Sci. 1999;40:1170-1176.
36. 2-Adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci. 1999;40:65-73.
37. Morrison JC, Moore CG, Deppmeier LM, et al. A rat model of chronic pressure-induced optic nerve damage. Exp Eye Res. 1997;64:85-96.
38. Neufeld AH, Sawada A, Becker B. Inhibition on nitric-oxide synthase 2 by aminoguanidine provides neuroprotection of retinal ganglion cells in a rat model of chronic glaucoma. Proc Natl Acad Sci U S A. 1999;96:9944-9948.
39. Gaasterland D, Kupfer C. Experimental glaucoma in the rhesus monkey. Invest Ophthalmol Vis Sci. 1974;13:455-457.
40. Sample PA, Bosworth CF, Weinreb RN. Short-wavelength automated perimetry and motion automated perimetry in glaucoma. Arch Ophthalmol. 1997;115:1129-1133.
41. Johnson CA, Adams AJ, Casson EJ, et al. Blue-on-yellow perimetry can predict the development of glaucomatous visual field loss. Arch Ophthalmol. 1993;111:645-650.
42. Weinreb RN. Assessment of optic disc topography for diagnosing and monitoring glaucoma. Arch Ophthalmol. 1998;116:1229-1231.
43. Weinreb RN. Evaluating the retinal nerve fiber layer in glaucoma with scanning laser polarimetry. Arch Ophthalmol. 1999;117:1403-1406.
44. Eriksson PS, Perfilieve E, Bojrk-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med. 1998;4:1313-1317.